Zhang YL, Yuan JQ, Wang KF et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7:78985–78993. https://doi.org/10.18632/oncotarget.12587

Article  PubMed  PubMed Central  Google Scholar 

Greenhalgh J, Boland A, Bates V et al First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation-positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 2021:CD010383. https://doi.org/10.1002/14651858.CD010383.pub3

Mok TS, Wu YL, Ahn MJ et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640. https://doi.org/10.1056/NEJMoa1612674

Article  CAS  PubMed  Google Scholar 

Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125. https://doi.org/10.1056/NEJMoa1713137

Article  CAS  PubMed  Google Scholar 

Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41–50. https://doi.org/10.1056/NEJMoa1913662

Article  CAS  PubMed  Google Scholar 

Nakagawa K, Garon EB, Seto T et al (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:1655–1669. https://doi.org/10.1016/S1470-2045(19)30634-5

Article  CAS  PubMed  Google Scholar 

Planchard D, Jänne PA, Cheng Y et al (2023) Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 389:1935–1948. https://doi.org/10.1056/NEJMoa2306434

Article  CAS  PubMed  Google Scholar 

Cho BC, Lu S, Felip E et al (2024) Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med 391:1486–1498. https://doi.org/10.1056/NEJMoa2403614

Article  CAS  PubMed  Google Scholar 

Stockhammer P, Grant M, Wurtz A et al (2024) Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. J Thorac Oncol 19:240–251. https://doi.org/10.1016/j.jtho.2023.10.001

Article  CAS  PubMed  Google Scholar 

Deng LL, Gao G, Deng HB, Wang F et al (2019) Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC. J Cancer Res Clin Oncol 145:2613–2624. https://doi.org/10.1007/s00432-019-03001-2

Article  CAS  PubMed  Google Scholar 

Blakely CM, Watkins TBK, Wu W et al (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693–1704. https://doi.org/10.1038/ng.3990

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin K, Hou H, Liang Y, Zhang X (2020) Prognostic value of TP53 concurrent mutations for EGFR and ALK-TKI-based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer 20:328. https://doi.org/10.1186/s12885-020-06805-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawaguchi T, Koh Y, Ando M et al (2016) Prospective analysis of oncogenic driver mutations and environmental factors: Japan molecular epidemiology for lung cancer study. J Clin Oncol 34:2247–2257. https://doi.org/10.1200/JCO.2015.64.2322

Article  CAS  PubMed  Google Scholar 

Tamiya A, Isa SI, Taniguchi Y et al (2021) Prospective observational study of treatment resistance-related gene screening using plasma circulating tumor DNA in third-generation EGFR-TKI osimertinib therapy (elucidator). Clin Lung Cancer 22:e336–e341. https://doi.org/10.1016/j.cllc.2020.05.023

Article  CAS  PubMed  Google Scholar 

Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009

Article  PubMed  Google Scholar 

Chen KC, Huang YH, Hsu KH, Tseng JS, Chang GC, Yang TY (2023) The role of neutrophil-to-lymphocyte ratio in advanced EGFR-mutant NSCLC patients treated with first-line osimertinib. Onco Targets Ther 16:317–326. https://doi.org/10.2147/OTT.S407301

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teranishi S, Sugimoto C, Nagaoka S et al (2022) Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib. Thorac Cancer 13:2741–2750. https://doi.org/10.1111/1759-7714.14608

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takamizawa S, Okuma Y, Kato Y, Hakozaki T, Kitagawa S, Zenke Y (2022) First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. Future Oncol 18:291–300. https://doi.org/10.2217/fon-2021-0947

Article  CAS  PubMed  Google Scholar 

Igawa S, Fukui T, Kasajima M et al (2022) First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: a prospective observational study. Invest New Drugs 40:430–437. https://doi.org/10.1007/s10637-021-01195-2

Article  CAS  PubMed  Google Scholar 

Taniguchi Y, Tamiya A, Osuga M et al (2024) Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naive EGFR-mutated NSCLC based on performance status. BMC Pulm Med 24:407. https://doi.org/10.1186/s12890-024-03212-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anai M, Inoue H, Saruwatari K et al (2024) Negative-predictive value of SUVmax for evaluating the efficacy of osimertinib in EGFR mutation-positive non-small cell lung cancer. Respir Investig 62:1072–1078. https://doi.org/10.1016/j.resinv.2024.09.001

Article  CAS  PubMed  Google Scholar 

Yoshimura A, Yamada T, Okuma Y et al (2021) Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. Transl Lung Cancer Res 10:3582–3593. https://doi.org/10.21037/tlcr-21-461

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu HA, Suzawa K, Jordan E et al (2018) Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res 24:3108–3118. https://doi.org/10.1158/1078-0432.CCR-17-2961

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishio M, Paz-Ares L, Reck M et al (2023) RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and clinical outcome. Clin Lung Cancer 24:415–428. https://doi.org/10.1016/j.cllc.2023.02.010

Article  CAS  PubMed  Google Scholar 

Lee JS, Kim EK, Kim KA, Shim HS (2024) Clinical impact of genomic and pathway alterations in stage I EGFR-mutant lung adenocarcinoma. Cancer Res Treat 56:104–114. https://doi.org/10.4143/crt.2023.728

Article  CAS  PubMed  Google Scholar 

Roeper J, Christopoulos P, Falk M et al (2022) TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR-mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res 11:4–13. https://doi.org/10.21037/tlcr-21-754

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tamiya A, Osuga M, Harada D et al (2024) Mechanisms of resistance and correlation between pretreatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer. Lung Cancer 195:107917. https://doi.org/10.1016/j.lungcan.2024.107917

Article  CAS  PubMed